NuCana (NASDAQ:NCNA) Trading 3.1% Higher – Still a Buy?

Shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) rose 3.1% during mid-day trading on Tuesday . The company traded as high as $2.1125 and last traded at $2.01. Approximately 24,723 shares changed hands during mid-day trading, a decline of 26% from the average daily volume of 33,347 shares. The stock had previously closed at $1.95.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a research report on Thursday, January 22nd. Wall Street Zen raised NuCana from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

NuCana Stock Up 3.1%

The company has a market capitalization of $60,300.00, a P/E ratio of -0.01 and a beta of 1.69. The firm has a fifty day simple moving average of $2.69 and a 200-day simple moving average of $3.52.

Institutional Investors Weigh In On NuCana

An institutional investor recently raised its position in NuCana stock. FNY Investment Advisers LLC increased its stake in shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,000 shares of the company’s stock after acquiring an additional 6,774 shares during the period. FNY Investment Advisers LLC owned about 33.33% of NuCana worth $36,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 44.00% of the company’s stock.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.